In this episode of Bio Eats World, we explore all the major revolutions in cancer treatment across the history of medicine—and what’s coming next. Hanne Winarsky delves into the past and future of the fight against cancer with Gary Reedy, CEO of the American Cancer Society; Jonathan Lim, CEO of Erasca, a biotech company with the mission of erasing cancer; and Jorge Conde, a16z general partner. The conversation spans not only the history of cancer treatment from the early days of surgery and the first radiology treatment (with an x-ray!), but also the fundamental nature of cancer—its origins, progressions, and how to stop it; the birth of precision genetic medicine and targeted therapies; our most powerful tools today (both low and high tech); and finally, the coming new tools and revolutions at the very cutting edge of cancer treatment.
- Investing in Phylo Jorge Conde and Zak Doric
- Operating on DNA is more like surgery than medicine Jorge Conde
- Fueling Innovation with Data with Arif Nathoo Arif Nathoo, Jorge Conde, Jay Rughani, Olivia Webb, and Kris Tatiossian
- Rare Disease, Big Impact with Matt Wilsey Jorge Conde, Matt Wilsey, Kris Tatiossian, and Olivia Webb
- Bioorthogonal Chemistry with Carolyn Bertozzi Carolyn Bertozzi, Jorge Conde, Kris Tatiossian, and Olivia Webb
Jonathan Lim
- Investing in Phylo Jorge Conde and Zak Doric
- Operating on DNA is more like surgery than medicine Jorge Conde
- Fueling Innovation with Data with Arif Nathoo Arif Nathoo, Jorge Conde, Jay Rughani, Olivia Webb, and Kris Tatiossian
- Rare Disease, Big Impact with Matt Wilsey Jorge Conde, Matt Wilsey, Kris Tatiossian, and Olivia Webb
- Bioorthogonal Chemistry with Carolyn Bertozzi Carolyn Bertozzi, Jorge Conde, Kris Tatiossian, and Olivia Webb
Gary Reedy
- Investing in Phylo Jorge Conde and Zak Doric
- Operating on DNA is more like surgery than medicine Jorge Conde
- Fueling Innovation with Data with Arif Nathoo Arif Nathoo, Jorge Conde, Jay Rughani, Olivia Webb, and Kris Tatiossian
- Rare Disease, Big Impact with Matt Wilsey Jorge Conde, Matt Wilsey, Kris Tatiossian, and Olivia Webb
- Bioorthogonal Chemistry with Carolyn Bertozzi Carolyn Bertozzi, Jorge Conde, Kris Tatiossian, and Olivia Webb
Hanne Winarsky
is the Head of Writer Acquisition & Development at Substack.
- Investing in Phylo Jorge Conde and Zak Doric
- Operating on DNA is more like surgery than medicine Jorge Conde
- Fueling Innovation with Data with Arif Nathoo Arif Nathoo, Jorge Conde, Jay Rughani, Olivia Webb, and Kris Tatiossian
- Rare Disease, Big Impact with Matt Wilsey Jorge Conde, Matt Wilsey, Kris Tatiossian, and Olivia Webb
- Bioorthogonal Chemistry with Carolyn Bertozzi Carolyn Bertozzi, Jorge Conde, Kris Tatiossian, and Olivia Webb
Insights, analysis, and additional reading on bio and health, and how both are shaping our future.
Learn MoreStreamlining the Patient Referrals Chain with Trey Holterman
From Chaos to Clarity in Data with Malinka Walaliyadde
Fueling Innovation with Data with Arif Nathoo
Want More Bio+Health?
Insights, analysis, and additional reading on bio and health, and how both are shaping our future.
Want More Bio+Health?
Insights, analysis, and additional reading on bio and health, and how both are shaping our future.
Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.
The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.
Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.
There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.
With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.
For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.